Why Vaccines May Work Differently in Obesity: What a New Mouse Study Suggests

As a bariatric and hepatobiliary surgeon, I spend a lot of my time thinking about weight not just in terms of how it affects the liver, the joints, or the heart, but in terms of everything it touches in the body — including, as it turns out, how well your immune system responds to a simple vaccine. Many of my patients are surprised to learn that obesity has long been associated with reduced vaccine effectiveness in humans, whether it's the annual flu shot or the hepatitis B vaccine. We've known this pattern exists for years, but we haven't fully understood why. A new laboratory study, published in The Journal of Immunology in April 2026 and led by Dr. Wendy L. Picking, offers an early but genuinely interesting biological explanation. I want to walk you through what the researchers found, and just as importantly, what this study does and does not tell us.

An Important Caveat Before We Begin

This was a mouse study, not a human clinical trial. The researchers vaccinated lean and obese mice against Pseudomonas aeruginosa, a bacterium that can cause serious, sometimes antibiotic-resistant infections such as pneumonia, and then studied how each group's immune system responded. Mouse immunology often mirrors human immunology in useful ways, which is why this kind of research is a standard and valuable first step in medicine — but it is still a step, not a final destination. Nothing here should be read as proof of exactly what happens in a human body. I'm sharing it because it helps explain a pattern we already see clinically, and because it points toward promising directions for future research, not because it changes what I'd recommend for your vaccination schedule today.

What the Researchers Found: Weaker Antibody Factories

When you receive a vaccine, your body is supposed to build germinal centers — specialized structures that form inside your lymph nodes, where immune cells called B cells mature, multiply, and learn to produce targeted antibodies against the vaccine's target. Think of germinal centers as training academies that turn out antibody-producing graduates. In this study, the obese mice's germinal centers didn't function as well as those in lean mice. As a result, the obese mice produced fewer antibodies after vaccination. Since antibody levels are the traditional yardstick we use to judge whether a vaccine has "worked," this finding gives us a plausible, cellular-level reason why obesity might blunt vaccine responses — the antibody factory itself appears to run less efficiently.

A Second Line of Defense the Researchers Didn't Expect

Here is where the study gets genuinely encouraging. Despite producing fewer circulating antibodies, the obese mice weren't defenseless. They developed strong populations of lung tissue-resident memory T cells — a separate category of immune cell that, instead of circulating through the blood, takes up permanent residence directly in lung tissue, standing guard at the site where a respiratory infection like Pseudomonas would actually strike. These lung-based defenders provided meaningful early protection against infection, even with the weaker antibody response. In other words, the obese mice's immune systems appeared to compensate for a weaker "blood antibody" strategy by leaning more heavily on a local, tissue-based strategy. It's a reminder that the immune system has more than one way to protect you, and that a single blood test for antibody levels doesn't necessarily tell the whole story of your protection.

Why This Matters for Patients Thinking About Surgery or Vaccination

For my patients, especially those preparing for bariatric surgery or simply keeping up with routine vaccines like the flu or pneumonia shot, I think this research is useful context rather than a reason for concern. It does not mean vaccines stop working in people with obesity, and it absolutely does not mean anyone should skip or delay a recommended vaccine. Vaccines still provide meaningful, real protection and remain strongly advised for my patients regardless of body weight. What this study does suggest is that researchers may eventually be able to design vaccines — particularly for lung and other mucosal infections — that specifically boost tissue-resident immunity in addition to blood antibody levels, potentially closing the effectiveness gap we currently see in obesity. It also reinforces something I already tell patients considering weight loss through lifestyle changes, medication, or surgery: the benefits of reaching a healthier weight extend well beyond blood pressure, joint pain, or liver health. A more robust and balanced immune response may turn out to be one more item on that list, though that connection still needs to be studied directly in humans.

The Bottom Line

This early mouse research from The Journal of Immunology (April 2026) offers one possible biological explanation for something clinicians have observed in humans for years: that obesity can blunt vaccine effectiveness. The likely culprit appears to be impaired germinal centers leading to lower antibody production, partly offset by a compensatory boost in lung-based tissue-resident memory T cells. None of this is proven in people yet, and none of it should change your vaccination plans on its own. If you have questions about the timing or type of vaccines you should receive, especially around a surgical procedure, please raise them with me or your primary care doctor so we can tailor the conversation to your individual health picture.